SoftServ's capabilities include full stack software development; security, accessibility and disaster recovery audits; mobile app development; containerization; Scientist.com marketplace configurations; and more.
SoftServ was created by Scientist.com's acquisition of Notch8 in Dec 2021. That same year, Scientist.com purchased HealthEconomics.Com, the world's largest Connected Community for the Value, Evidence and Market Access industry; InsideScientific, an online marketing content creator for the life sciences; and BioPharmCatalyst, a research-based portal that provides key catalyst updates for publicly traded biotech companies.
Scientist.com operates online marketplaces for most of the world's top 30 pharmaceutical companies, 120+ biotech companies and the US National Institutes of Health. The award-winning digital research platform helps life scientists test more ideas in less time.
Scientist.com's mission is to empower and connect scientists worldwide.
The company's digital research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost.
Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management.
Scientist.com connects researchers at the world's top pharmaceutical companies, biotechnology companies, and the US National Institutes of Health to the world's largest network of scientific research suppliers.
Opsidio doses first subject in OpSCF Phase 2a clinical trial
OncoResponse commences first subject dosing in OR502 Phase one/two trial
Photocure's partner Asieris Pharmaceuticals advances Hexvix NDA in China
Eli Lilly to open Lilly Gateway Labs in San Diego in H1 2024
Carisma Therapeutics' CT-0525 IND application receives US FDA approval
MedGenome names new Advisory Board chairman
NanoVibronix initiates clinical study for UroShield at University of Michigan
Acrivon Therapeutics secures FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Fusion Antibodies signs OptiMAL collaboration agreement with US National Cancer Institute
GeNeuro completes recruitment for long-COVID trial, anticipates top-line results by June 2024